8-K: CalciMedica Faces Nasdaq Delisting Threat

CalciMedica, Inc. received notices from Nasdaq regarding non-compliance with minimum market value and bid price requirements, risking delisting.

Summary

• CalciMedica, Inc. received a notice from Nasdaq on March 13, 2026, indicating non-compliance with Listing Rule 5550(b)(2) because its market value of listed securities (MVLS) had been below the minimum $35,000,000 for 30 consecutive business days.
• Nasdaq also noted non-compliance with Listing Rules 5550(b)(1) (stockholders' equity of at least $2,500,000) and 5550(b)(3) (net income of $500,000).
• The company has 180 calendar days, until September 9, 2026, to regain compliance with the MVLS requirement.
• On March 16, 2026, CalciMedica received a separate notice from Nasdaq for non-compliance with Listing Rule 5550(a)(2), as its common stock's minimum bid price had been below $1.00 per share for 30 consecutive business days.
• The company has 180 calendar days, until September 14, 2026, to regain compliance with the Minimum Bid Price Requirement.
• To regain MVLS compliance, the market value must close at $35,000,000 or more for a minimum of 10 consecutive business days, or the company must meet the stockholders' equity or net income alternatives.
• To regain Minimum Bid Price compliance, the stock must close at $1.00 or more per share for a minimum of 10 consecutive business days.
• Non-compliance has no immediate effect on the listing or trading of the company's common stock on The Nasdaq Capital Market.
• The company intends to monitor listing requirements and consider options like a reverse stock split to regain compliance.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative development, indicating severe market underperformance and potential loss of public market access, which could hinder future financing and investor confidence. The multiple non-compliance issues suggest deep-seated challenges.

Negatives

• Non-compliance with Nasdaq's minimum market value of listed securities requirement ($35,000,000).
• Non-compliance with Nasdaq's minimum bid price requirement ($1.00 per share).
• Potential delisting from The Nasdaq Capital Market if compliance is not regained.
• Company also noted as not meeting stockholders' equity ($2,500,000) and net income ($500,000) alternative listing standards.

Risks

• Risk of delisting from The Nasdaq Capital Market if the company fails to regain compliance with MVLS or Minimum Bid Price requirements within the specified periods.
• Uncertainty regarding the company's ability to regain compliance, despite considering options like a reverse stock split.
• A reverse stock split, while a potential solution for bid price, can be perceived negatively by investors and may not address underlying operational issues.

Future Outlook

The company intends to actively monitor Nasdaq listing requirements and will consider available options to regain compliance, including a reverse stock split. However, there is no assurance that the company will be able to regain or maintain compliance with Nasdaq's continued listing requirements.

Management Comments

• "The Company intends to actively monitor the Nasdaq listing requirements and will consider available options to regain compliance with the listing requirements, including such actions as a reverse stock split."
• "There can be no assurance that the Company will be able to regain compliance with the applicable Nasdaq continued listing requirements or otherwise maintain compliance with the other listing requirements."

Industry Context

StockSavvy.ai notes that non-compliance with listing standards is a common challenge for smaller biotechnology or early-stage companies, often reflecting market skepticism about their pipeline or financial stability. Such notices can further erode investor confidence and liquidity, making it harder to attract capital and maintain a public profile essential for growth in the capital-intensive biotech sector.

Comparison to Industry Standards

• StockSavvy.ai observes that maintaining Nasdaq listing standards is a fundamental requirement for public companies. Companies like CalciMedica, facing both MVLS and bid price deficiencies, are in a precarious position, unlike more established biotech firms such as Amgen or Gilead Sciences which consistently meet these thresholds.
• The consideration of a reverse stock split is a common tactic for companies struggling with bid price, but it often signals underlying operational or financial struggles, contrasting with companies that grow organically to maintain compliance.
• The simultaneous failure to meet stockholders' equity and net income alternatives further highlights the company's distance from typical financial health benchmarks for publicly traded entities in the biotech space.

Stakeholder Impact

• Shareholders face potential delisting, which could lead to reduced liquidity, difficulty in trading shares, and a negative impact on share price.
• A potential reverse stock split could alter share structure and perception, though it aims to prevent delisting.
• Employees and management face uncertainty regarding the company's public market status and future strategic options.

Next Steps

• Actively monitor Nasdaq listing requirements.
• Consider available options to regain compliance, including a reverse stock split.
• Regain compliance with MVLS requirement by September 9, 2026.
• Regain compliance with Minimum Bid Price requirement by September 14, 2026.

Key Dates

Recommendation

The company is facing imminent delisting from Nasdaq due to severe non-compliance with both market value and minimum bid price requirements, as well as not meeting alternative financial standards. While a reverse stock split is an option, it often signals deeper issues and can be dilutive or negatively perceived by the market. The risk of losing public market access is substantial, making the stock a high-risk investment with significant downside potential and limited prospects for near-term recovery.

Keywords

CalciMedica, CALC, Nasdaq, Delisting, Compliance, Market Value of Listed Securities, Minimum Bid Price, Reverse Stock Split, SEC Filing, 8-K